Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Merck KGaA/Symphogen, Valeant/Medicis, Medivir/Novadex

Executive Summary

Achillion brought in nearly $42 million in its third large fundraising over the past 24 months, but the virology-focused biotech may become an increasingly sought acquisition target as other hepatitis C candidates face hurdles or are shelved entirely.

You may also be interested in...



Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis

The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.

Merck KGaA Changes Manager Incentives, But Stays Mum On Job Losses

Germany's Merck KGaA implements share-based incentive scheme for top management and vows to improve financial transparency, while discussing cost-savings with employees.

High-Premium Buyouts Continue In Hepatitis C Space; Are Idenix And Achillion Next?

Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel